Ads
related to: genentech
Search results
Americans to get one-time payment from new $250,000 401k settlement
The US Sun· 4 days agoTHOUSANDS of Americans are eligible for a one-time payout of an undisclosed amount following the...
Genprex dosing subjects in trial of combination therapy for small-cell lung cancer
Clinical Trials Arena via Yahoo Finance· 17 hours agoThe Acclaim-3 trial aims to determine the safety and optimal dosage of Reqorsa (quaratusugene...
Earnings call: Lineage Cell Therapeutics reports positive OpRegen trial results By Investing.com
Investing.com· 5 days agoIn a recent earnings call, Lineage Cell Therapeutics (NYSE:LCTX), a biotechnology company...
Spyre Therapeutics names Sandra Milligan to board By Investing.com
Investing.com· 11 hours agoSpyre Therapeutics, Inc. (NASDAQ: SYRE), a biotechnology company focusing on the development of...
Takeda pays AC Immune $100M upfront for Alzheimer's drug as phase 2 readout nears
FierceBiotech· 3 days agoTakeda may be paring back its R&D pipeline in the name of efficiency, but the Japanese pharma has...
Q1 2024 Lineage Cell Therapeutics Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 5 days agoData is a major driver of value, and that data was notable for several reasons, and I just want to ensure those points are clear for our new and existing shareholders. Last Friday, on behalf ...
Federal Circuit Reiterates That an Alleged Infringer’s Intent Is Irrelevant in a Hatch-Waxman Safe...
JD Supra· 7 days agoThe Federal Circuit considered the relevance of an alleged infringer’s intent in a safe harbor analysis in Edwards Lifesciences Corp. v. Meril Life Scis. Pvt.1 The District Court had previously ...
The most innovative Mother’s Day campaigns from Dove, MoneyGram, DoorDash & more
The Drum· 6 days agoFrom heartwarming reunions facilitated by DoorDash to MullenLowe planting career opportunities for...
Reveal Genomics HER2DX Assay to Be Prospectively Evaluated in ECOG-ACRIN Trial
GenomeWeb News· 1 day agoThe Phase II CompassHER2 pCR trial is evaluating whether neoadjuvant treatment with paclitaxel and Genentech's HER2-targeted drugs Herceptin (trastuzumab) and Perjeta (pertuzumab ...
Earnings call: Lonza maintains outlook despite Q1 performance lag By Investing.com
Investing.com· 1 day agoLonza Group AG (LONN.SW), a global leader in life sciences, reported a softer performance in the...
